Moleculin Biotech (NASDAQ:MBRX) Stock Rating Upgraded by Maxim Group

Moleculin Biotech (NASDAQ:MBRX) was upgraded by analysts at Maxim Group from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday,Benzinga reports. The firm presently has a $4.00 target price on the stock. Maxim Group’s price objective would suggest a potential upside of 273.83% from the company’s previous close.

MBRX has been the subject of several other reports. StockNews.com began coverage on shares of Moleculin Biotech in a research report on Thursday, March 13th. They issued a “sell” rating for the company. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Moleculin Biotech in a research report on Monday.

Moleculin Biotech Stock Down 7.0 %

Shares of NASDAQ MBRX opened at $1.07 on Tuesday. The business has a fifty day moving average price of $1.32 and a two-hundred day moving average price of $1.99. Moleculin Biotech has a fifty-two week low of $0.40 and a fifty-two week high of $6.23.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.